Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential

Yu Zhang; Xiangxiang Zhou

doi:10.1016/j.biopha.2024.116667

Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential

Biomed Pharmacother. 2024 May 3:175:116667. doi: 10.1016/j.biopha.2024.116667. Online ahead of print.

Authors

Yu Zhang¹, Xiangxiang Zhou²

Affiliations

¹ Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.
² Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China; Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, China; Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China; Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong 250021, China; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou 251006, China. Electronic address: xiangxiangzhou@sdu.edu.cn.

PMID: 38703504
DOI: 10.1016/j.biopha.2024.116667

Abstract

Regulated cell death (RCD) is a form of cell death that can be regulated by numerous biomacromolecules. Accumulating evidence suggests that dysregulated expression and altered localization of related proteins in RCD promote the development of cancer. Targeting subroutines of RCD with pharmacological small-molecule compounds is becoming a promising therapeutic avenue for anti-tumor treatment, especially in hematological malignancies. Herein, we summarize the aberrant mechanisms of apoptosis, necroptosis, pyroptosis, PANoptosis, and ferroptosis in hematological malignancies. In particular, we focus on the relationship between cell death and tumorigenesis, anti-tumor immunotherapy, and drug resistance in hematological malignancies. Furthermore, we discuss the emerging therapeutic strategies targeting different RCD subroutines. This review aims to summarize the significance and potential mechanisms of RCD in hematological malignancies, along with the development and utilization of pertinent therapeutic strategies.

Keywords: Hematological malignancies; Regulated cell death; Targeted therapy.

Publication types

Review